• / Free eNewsletters & Magazine
  • / My Account
Home>European Commission

European Commission

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. Scania Interim Report January–June 2016

    Scania Interim Report January–June 2016

  2. Ontex H1 2016: Solid reported revenue growth and margins in competitive markets and Mabe integration on track

    Ontex H1 2016: Solid reported revenue growth and margins in competitive markets and Mabe integration on track

  3. Telefónica Profit Plunges on Currency Moves -- Update

    Telefónica Profit Plunges on Currency Moves -- Update

  4. Post-Brexit Uncertainties Rattle U.K. Businesses, But Minimal Effect on European Counterparts

    Post-Brexit Uncertainties Rattle U.K. Businesses, But Minimal Effect on European Counterparts

  5. Post-Brexit Uncertainties Rattle U.K. Businesses, But Minimal Effect on European Counterparts -- 2nd Update

    Post-Brexit Uncertainties Rattle U.K. Businesses, But Minimal Effect on European Counterparts -- 2nd Update

  6. Michel Barnier Appointed as Chief Brexit Negotiator

    Michel Barnier Appointed as Chief Brexit Negotiator

  7. UPDATE: Why Italy's banks could ignite a eurozone crisis

    UPDATE: Why Italy's banks could ignite a eurozone crisis

  8. Scania Contests the European Commission ’s View, but Still Makes Provision

    Scania Contests the European Commission ’s View, but Still Makes Provision

  9. EU Approves a Monsanto Biotech Bean -- WSJ

    EU Approves a Monsanto Biotech Bean -- WSJ

  10. Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy

    Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.